BC Innovations | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BC Extra | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

Sanofi’s deal for Synthorx shows its continued commitment to building an innovative pipeline in oncology, an area of increasing importance to the pharma, by obtaining both a clinical program targeting IL-2 and a platform it...
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

With a steady stream of small investments from the Van Herk Group, DCprime is now poised to raise its next financing from a broader group of investors to expand the Dutch cancer vaccine company’s product...
BC Extra | Aug 6, 2019
Company News

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

CAR T therapy company Allogene Therapeutics Inc . (NASDAQ:ALLO) hired Rafael G. Amado as EVP of R&D and CMO, effective Sept. 3. He was president of R&D at Adaptimmune Therapeutics plc (NASDAQ:ADAP). Allogene Executive Chairman and...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Extra | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
BioCentury | May 7, 2019
Finance

Confo’s €30M growth plan

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round,...
BioCentury | Apr 30, 2019
Finance

Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the...
BC Week In Review | Feb 8, 2019
Clinical News

FDA approves Sanofi's Cablivi for rare clotting disease

Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Cablivi caplacizumab-yhdp to treat acquired thrombotic thrombocytopenic purpura (aTTP), making it the first FDA-approved therapy for the rare blood clotting disorder. Sanofi will launch the drug late this quarter...
BC Extra | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

Astellas Pharma Inc. (Tokyo:4503) said President of Pharmaceutical Technology Mitsunori Matsuda and President of Asia & Oceania Business Masatoshi Kuroda will resign, effective June 18. Hideki Shima will succeed Matsuda. Cancer and rare diseases company...
Items per page:
1 - 10 of 394
BC Innovations | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BC Extra | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

Sanofi’s deal for Synthorx shows its continued commitment to building an innovative pipeline in oncology, an area of increasing importance to the pharma, by obtaining both a clinical program targeting IL-2 and a platform it...
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

With a steady stream of small investments from the Van Herk Group, DCprime is now poised to raise its next financing from a broader group of investors to expand the Dutch cancer vaccine company’s product...
BC Extra | Aug 6, 2019
Company News

Management tracks: Allogene snags Adaptimmune's Amado; plus Foundation Medicine, CymaBay and more

CAR T therapy company Allogene Therapeutics Inc . (NASDAQ:ALLO) hired Rafael G. Amado as EVP of R&D and CMO, effective Sept. 3. He was president of R&D at Adaptimmune Therapeutics plc (NASDAQ:ADAP). Allogene Executive Chairman and...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BC Extra | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
BioCentury | May 7, 2019
Finance

Confo’s €30M growth plan

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round,...
BioCentury | Apr 30, 2019
Finance

Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the...
BC Week In Review | Feb 8, 2019
Clinical News

FDA approves Sanofi's Cablivi for rare clotting disease

Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Cablivi caplacizumab-yhdp to treat acquired thrombotic thrombocytopenic purpura (aTTP), making it the first FDA-approved therapy for the rare blood clotting disorder. Sanofi will launch the drug late this quarter...
BC Extra | Feb 6, 2019
Company News

Management tracks: Astellas, Blueprint

Astellas Pharma Inc. (Tokyo:4503) said President of Pharmaceutical Technology Mitsunori Matsuda and President of Asia & Oceania Business Masatoshi Kuroda will resign, effective June 18. Hideki Shima will succeed Matsuda. Cancer and rare diseases company...
Items per page:
1 - 10 of 394